Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 28, 2026
TickeronGET DAILY SIGNALS
Align Technology (ALGN) Delivers Q3 Revenue Growth and EPS Beat

Align Technology (ALGN) Delivers Q3 Revenue Growth and EPS Beat

Key Takeaways

  • Align Technology reported Q3 2026 revenue of $1.015 billion, up 1.9% year over year and slightly above the roughly $1.01 billion consensus estimate.
  • Adjusted (non-GAAP) diluted earnings per share came in at $2.80, beating analyst expectations of approximately $2.78; GAAP diluted EPS was $1.90.
  • Clear Aligner revenue rose 4.2% to $839.3 million, while Imaging Systems and CAD/CAM Services revenue declined 7.6% to $175.5 million.
  • Non-GAAP operating margin improved to 24.4%, above guidance, even as softer discretionary dental spending weighed on demand.
  • Management guided Q4 2026 revenue to a range of $1.00 billion to $1.02 billion, below the consensus of about $1.05 billion at the time.
  • For more context, readers can explore Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages for ALGN.
  • Investors seeking additional market insights can also explore Trending AI Robots for AI-driven trading ideas.

Earnings Context and Why It Matters

Align Technology, the maker of the Invisalign clear aligner system and iTero intraoral scanners, serves as a useful indicator for consumer discretionary healthcare spending. Because aligner treatment is often elective and self-funded, the company’s results provide an early signal on dental-industry demand and patient confidence. Heading into the report, analysts had noted weakening U.S. clear aligner volumes and trimmed estimates, with several firms lowering their ratings on the stock. The Q3 print therefore mattered less for top-line growth alone than for evidence that Align could defend profitability and clear aligner volumes in a softening demand environment while positioning its digital platform and scanner ecosystem for a recovery. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Reported Results

For the third quarter of 2026, Align Technology reported total revenue of $1.015 billion, a 1.9% increase from the prior-year quarter’s $995.7 million and modestly above consensus of roughly $1.01 billion. Clear Aligner revenue grew 4.2% year over year to $839.3 million, driven by a 6.6% increase in shipments to a record 690,635 cases. Imaging Systems and CAD/CAM Services revenue fell 7.6% to $175.5 million, reflecting softer capital equipment investment.

Net income climbed to $135.0 million from $56.8 million a year earlier. GAAP diluted earnings per share reached $1.90, compared with $0.78 in Q3 2025. On an adjusted (non-GAAP) basis, diluted EPS was $2.80, slightly ahead of the consensus of about $2.78. GAAP gross margin was 68.7% and non-GAAP gross margin was 70.4%, while non-GAAP operating margin of 24.4% came in above the company’s outlook, supported by disciplined expense management and productivity gains.

For Q4 2026, management guided revenue to between $1.00 billion and $1.02 billion, below the consensus of approximately $1.05 billion, and reiterated full-year 2026 revenue of $4.11 billion to $4.13 billion. The company also expects to repurchase up to $300 million of stock in Q4.

Market Reaction and Investor Sentiment

Sentiment into the report was cautious. Analysts had spent October lowering price targets and, in some cases, downgrading the stock amid signs of soft U.S. clear aligner demand and a weaker dental economy. Align’s adjusted EPS beat and in-line revenue were offset by Q4 guidance that fell short of consensus, underscoring management’s expectation that softer discretionary healthcare spending and cautious capital equipment purchasing will persist. The mixed setup—better-than-expected profitability against a lighter forward outlook—left investors weighing resilient margins and international growth against a still-tempered near-term demand picture. From what I see, this balance is important because it highlights how the company is managing through the current environment.

Forward Outlook and Key Factors to Monitor

Align’s fourth-quarter outlook signals that the company expects the challenging demand environment to continue. Management attributed the reduced 2026 revenue expectations to two factors: a lower Systems and Services revenue outlook tied to a mix shift toward lower-priced scanners and more flexible acquisition models, and slightly lower Clear Aligner volume and average selling price (ASP) assumptions driven by product and geographic mix plus foreign exchange.

Investors should watch several signals in the coming quarters. First, clear aligner volume and ASP trends will indicate whether demand is stabilizing or still deteriorating, particularly in North America. Second, iTero scanner placements and the shift toward flexible purchasing models will shape the profitability of the Systems & Services segment. Third, margin execution remains a bright spot, and continued expense discipline will be key to protecting operating margin as revenue growth moderates.

Longer term, Align’s investments in direct 3D printing, the NXT Technology platform, and new product categories such as the Invisalign Sports Guard represent potential growth levers, while its roughly $500 million share repurchase plan for 2026 signals management confidence. A sustained recovery in discretionary dental spending remains the primary catalyst to watch. I’m watching this closely as the next few quarters unfold.

Exploring AI-Powered Research Tools

In my own research process I often turn to Tickeron’s AI Screener to quickly filter stocks by technical patterns, fundamentals, and industry trends. It helps surface ideas and monitor setups like those around ALGN without manually scanning dozens of screens. The tool has become a regular part of how I compare companies and spot potential opportunities in the market.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ALGN

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


ALGN's RSI Oscillator recovers from overbought zone

The 10-day RSI Oscillator for ALGN moved out of overbought territory on November 11, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 instances where the indicator moved out of the overbought zone. In 19 of the 24 cases the stock moved lower in the days that followed. This puts the odds of a move down at 79%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 63 cases where ALGN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 68%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.

ALGN broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on ALGN as a result. In 59 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.

ALGN moved above its 50-day moving average on November 02, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for ALGN crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 7 of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 64%.

Following a +9.34% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALGN advanced for three days, in 187 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.

The Aroon Indicator entered an Uptrend today. In 153 of 206 cases where ALGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 74%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 31 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. ALGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.786) is normal, around the industry mean (4.964). P/E Ratio (28.769) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (0.611) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (2.612) is also within normal values, averaging (56.876).

The Tickeron SMR rating for this company is 69 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

Notable companies

The most notable companies in this group are Intuitive Surgical (NASDAQ:ISRG), Align Technology (NASDAQ:ALGN).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 9.78B. The market cap for tickers in the group ranges from 126 to 159.96B. ISRG holds the highest valuation in this group at 159.96B. The lowest valued company is HGYMF at 126.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was -6%. For the same Industry, the average monthly price growth was 1%, and the average quarterly price growth was 8%. AZTA experienced the highest price growth at 13%, while BNGO experienced the biggest fall at -23%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was 4%. For the same stocks of the Industry, the average monthly volume growth was -30% and the average quarterly volume growth was -26%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 57
P/E Growth Rating: 54
Price Growth Rating: 50
SMR Rating: 81
Profit Risk Rating: 94
Seasonality Score: 24 (-100 ... +100)
AI Screener 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of the invisalign system for treating malocclusion

Industry PharmaceuticalsOther

Industry
Medical Specialties
Address
410 North Scottsdale Road
Phone
+1 602 742-2000
Employees
20290
Web
https://www.aligntech.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SAP's U.S. shares fell from Monday's close of $233.83 to $221.99 by late Tuesday morning in New York, a -5.06% decline recorded during regular trading hours. The company-specific trigger was the announced exit of Chief Customer Officer Thomas Saueressig, an executive board member since 2019, who will leave at the end of March 2027 to become CEO of IONOS; the disclosure came before the U.S. open.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.